1) Efforts of RIKEN BRC promoting COVID-19 related research
RIKEN BioResource Research Center (BRC) is a unique repository in the world, as it collects and distributes bioresources of three different levels, i.e., genetic materials (genomic and cDNA clones) and cell lines of human and animal origins as well mouse strains. With this unique feature, RIKEN BRC hopes to contribute to the comprehensive research and development on COVID-19. The research and developments have been focusing on the following four subjects: 1) SARS-CoV-2 infection and proliferation, 2) Pathogenesis and host defense, 3) Disease progression to clinically severe cases and 4) Development of effective therapies of COVID-19 patients and preventive vaccines against SARS-CoV-2 infection.
Lists of mouse strains and DNA clones useful for COVID-19 R&D from RIKEN BRC are available from following links:
Mouse resources for COVID-19 research. (Experimental Animal Division)
Human genes for COVID-19 research. (Gene Engineering Division)
2)Deposited cell lines
3) Papers regarding COVID-19 research in which the cell lines we have provided were used.
4) Papers regarding COVID-19 research in which the cell lines we can provide were used.
| BRC Cell Line | Cell Line | Reference |
1 | Vero E6
RCB0988 CACO-2
Calu-3
RCB2202 293T
RCB1366 HuH-7 | Vero E6
Caco-2
Calu-3
HEK293T
Huh7 | In Vitro and Animal Models for SARS-CoV-2 research |
2 | Vero E6
RCB1366 HuH-7
RCB2202 293T
RCB0098 A549, RCB3677 A549
EFKB3 | Vero E6
Vero
HUH 7.0
293T
A549
EFKB3 | Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States |
3 | Vero
RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1366 HuH-7 | Vero
HeLa
HEK293T/F
Huh7 | A Thermostable mRNA Vaccine against COVID-19 |
4 | RCB1637 293
RCB2202 293T
RCB0098 A549, RCB3677 A549
RCB0218 MRC-5, known PDL
Vero E6
Vero 81
RCB0007 HeLa, RCB3680 HeLa
RCB1366 HuH-7 | 293
293T
A549
MRC5
Vero E6
Vero 81
HeLa
Huh7 | Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |
5 | RCB1648 Hep G2
RCB1366 HuH-7
RCB2202 293T
Vero
CHO
RCB0995 MDCK | HepG2
Huh-7
293T
Vero
CHO
MDCK | Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 |
6 | Vero E6
RCB1366 HuH-7 | Vero E6
Huh-7 | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
7 | Vero E6
RCB1366 HuH-7 | Vero E6
Huh-7 | Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway |
8 | Vero E6
RCB1366 HuH-7 | Vero E6
Huh-7 | Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) |
9 | Vero E6
RCB1366 HuH-7 | Vero E6
Huh-7 | A pneumonia outbreak associated with a new coronavirus of probable bat origin |
10 | RCB1637 293
RCB1366 HuH-7
RCB1423 BHK-21
Vero E6 | HEK293
Huh-7
BHK21
Vero-E6 | Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε |
11 | RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1423 BHK-21
RCB0988 CACO-2 | HeLa
293T
BHK-21
Caco-2 | COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome |
12 | RCB0988 CACO-2 | Caco-2 | Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |
13 | RCB0988 CACO-2 | Caco-2 | A metabolic handbook for the COVID-19 pandemic |
14 | RCB2202 293T
RCB0098 A549, RCB3677 A549
BHK
RCB0988 CACO-2
RCB1366 HuH-7
PK-15 | 293T
A549
BHK
Caco-2
Huh-7.5
PK-15 | Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses |
15 | RCB2202 293T
RCB0098 A549, RCB3677 A549 | HEK293T
A549 | Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |
16 | RCB2202 293T
RCB0007 HeLa, RCB3680 HeLa
Calu-3
RCB0218 MRC-5, known PDL | HEK293T
HeLa
Calu-3
MRC-5 | Cell entry mechanisms of SARS-CoV-2 |
17 | RCB2202 293T
HEK293F
RCB0007 HeLa, RCB3680 HeLa
RCB0218 MRC-5, known PDL | HEK293T
HEK293F
HeLa
MRC5 | Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |
18 | RCB1366 HuH-7
Huh-7.5 | Huh-7
Huh-7.5 | Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication |
19 | MA104
RCB1637 293 | MA104
HEK293 | TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes |
20 | RCB0218 MRC-5, known PDL | MRC-5 | Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells |
21 | Fcwf-4
A72
RCB0995 MDCK
DH82 | Fcwf-4
A72
MDCK
DH82 | Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663 |
22 | GES-1
RCB1189 THP-1,RCB3686 THP-1 | GES-1
THP-1 | Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels |